secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008277
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports 39% ORR in Cohort 2 of [212Pb]VMT-α-NET trial; safety cleared at 6.0 mCi
--------------------------------------------------------------------------------

- Updated interim data from Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-expressing NETs at ASCO-GI.
- Objective response rate of 39% (9/23) in Cohort 2 per RECIST v1.1; 8 confirmed, 1 pending.
- 76% (19/25) of evaluable patients without progression and alive; deepening of best response seen in 7 patients.
- DLT assessment completed for Cohort 3 (6.0 mCi); cleared to enroll more; one additional patient already treated.
- No DLTs, treatment-related discontinuations, or serious renal complications across 56 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526008277/0001193125-26-008277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526008277/catx-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer